Diversification is the buzz word in pharmaceuticals as the feared 2010-2012 patent "cliff" looms nearer, when many of world's top medicines lose patent protection. New Glaxo CEO Andrew Witty, 43, is embracing the concept wholeheartedly via a bold deal with South Africa's Aspen that takes the world's second biggest drugmaker into generics in emerging markets and a strategy to broaden [...] ...
Anytime
